Dimerix

Dimerix Financing Cash Flow

The Net Financing Cash Flow of Dimerix (DXB.AX) as of Oct 11, 2026 is 118,468.00 AUD. In the previous year, Net Financing Cash Flow was 7.42 M AUD — a change of -98.40% (lower).

Financing Cash Flow

118,468.00AUD

YoY

-98.40%

Last updated:

Net Financing Cash Flow of Dimerix is 2026 118,468.00 AUD. Net Financing Cash Flow of Dimerix was 2025 7.42 M AUD. It decreases by -98.40% lower compared to the previous year.

The Dimerix Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2019
8.91 M AUD
Jan 1, 2020
8.91 M AUD
Jan 1, 2021
3.83 M AUD
Jan 1, 2022
17.69 M AUD
Jan 1, 2023
11.07 M AUD
Jan 1, 2024
21.17 M AUD
Jan 1, 2025
7.42 M AUD
Jan 1, 2026
118,468.00 AUD
The Dimerix Financing Cash Flow history
YEARFinancing Cash FlowYoY
118,468.00AUD-98.40%
7.42 MAUD-64.94%
21.17 MAUD+91.22%
11.07 MAUD-37.42%
17.69 MAUD+362.47%
3.83 MAUD-57.07%
8.91 MAUD0.00%
8.91 MAUD+22.96%
7.25 MAUD+246.29%
2.09 MAUD-10,648.25%
-19,840.00AUD-100.84%
2.37 MAUD+2,819.57%
81,295.00AUD—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Net Financing Cash Flow of Dimerix is 118,468.00 AUD in 2026.

Net Financing Cash Flow of Dimerix changed from 7.42 M AUD to 118,468.00 AUD, representing a -98.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Dimerix since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Dimerix historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Dimerix

All Key Metrics — Dimerix